(RTTNews) - Stereotaxis, Inc. (STXS), a surgical robotics company for minimally invasive endovascular interventions, announced on Thursday that it has received its first firm order for its next-generation robotic system, GenesisX.
The order, placed by a pioneering European hospital, marks a critical milestone as the company prepares for the full commercial launch of GenesisX.
This innovative robotic system enhances accessibility to Robotic Magnetic Navigation technology, which will be transformative for endovascular surgery.
GenesisX features a compact design with smaller magnets and integrated magnetic shielding, offering significant improvements in speed, responsiveness, and workflow.
It also operates with standard 120/230V power outlets and requires no structural anchoring, making it easier to implement in clinical settings.
With CE Mark already obtained in Europe and FDA submission underway, Stereotaxis plans to expand its portfolio of compatible catheters and achieve additional regulatory approvals in both Europe and the U.S. throughout 2025.
Stereotaxis is set to revolutionize the field of minimally invasive surgery, and this first order for GenesisX marks an important step in advancing robotic adoption in the operating room.
Currently, STXS is trading at $2.35 up by 4.86%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
